updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
Published 1 year ago • 129 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
0:50
investigating mechanisms of resistance to cdk4/6 inhibitors
-
0:53
final results of the phase 3 data trial assessing aromatase inhibition in hr breast cancer
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
1:25
current state of cdk4/6 inhibitors in metastatic her2-negative breast cancer
-
36:14
tumor immunology
-
4:51
are there other options to treat breast cancer rather than chemotherapy?
-
1:54
cell cycle inhibitors - cdk4/6 inhibitors
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
2:12
os results of the precious trial: pertuzumab retreatment in her la/mbc
-
23:00
emerald trial: an analysis of key biomarkers and patient subgroups
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
4:17
puccini: early metabolic response predicts survival in patients with mbc receiving cdk4/6 inhibitors
-
1:30
results of the phase ii geparnuevo trial
-
3:38
emerald-1 trial in hcc
-
1:56
vepdegestrant palbociclib in er metastatic breast cancer: phase ib trial results
-
0:51
emerald-1 trial: improved pfs w/ durvalumab bevacizumab tace vs tace in hepatocellular carcinoma
-
1:57
monarcher: final os results of abemaciclib in hr , her breast cancer